Smith & Nephew plc (SN.L)

979,20 -4,80 (-0,49%) In data: 01:59PM BST. Mercato aperto.

Smith & Nephew plc

Building 5
Croxley Park Hatters Lane
Watford WD18 8YE
United Kingdom
44 1923 477 100
https://www.smith-nephew.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 18.452

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Deepak S. Nath Ph.D.	CEO & Director	3,72M	N/D	1972
Mr. John Terence Rogers	CFO & Executive Director	N/D	N/D	1969
Mr. Paul Connolly	President of Global Operations	N/D	N/D	1968
Mr. Andrew Swift	Vice President of Investor Relations	N/D	N/D	N/D
Ms. Helen Barraclough	Group General Counsel & Company Secretary	N/D	N/D	1979
Ms. Alison Parkes	Chief Compliance Officer & Compliance APAC	N/D	N/D	1972
Mr. Joe Metzger	Senior Vice President of Marketing Services & Communications	N/D	N/D	N/D
Mr. Philip G. Cowdy	Chief Corporate Development & Corporate Affairs Officer	N/D	N/D	1967
Ms. Elga Lohler	Chief Human Resources Officer	N/D	N/D	1968
Dr. Vasant Padmanabhan Ph.D.	President of Research & Development and Ear, Nose & Throat	N/D	N/D	1967

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in GBp.

Descrizione

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di Smith & Nephew plc al 1 aprile 2024 è 4. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.